HIV-associated lipodystrophy syndrome

Pharmacotherapy

Volumn 20, Issue 1 I, 2000, Pages 13-22

  Qaqish, Roula B ^a,c   Fisher, Evelyn ^c   Rublein, John ^a   Wohl, David A ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DIABETES MELLITUS; DISEASE DURATION; DRUG INDUCED DISEASE; GLUCOSE TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; PATIENT SELECTION; REVIEW;

EID: 0033986492     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.1.13.34667     Document Type: Review

References (52)

1. Patella FJ Jr, Delaney KM, Moorman AC, et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Chiasson MA, Brenson L, Li W, et al. Accelerating decline in New York City AIDS mortality [abstr]. In: Program and Abstracts of the 5th Conference on Retrovirus and Opportunistic Infections, Chicago, February 2-6, 1998.
3. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in death from AIDS due to new antiretrovirals [letter] Lancet 1997;349:1294.
4. Visnegarwala F, Krause KL, Musher DL. Severe diabetes associated with protease inhibitor therapy [letter]. Ann Intern Med 1997;127:947.
5. Eastone J, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor [letter], Ann Intern Med 1997;127:948.
6. Dong BJ, Gruta CI, Legg JJ. Diabetes and use of protease inhibitor [abstr]. In: Program and Abstracts of the 12th World AIDS conference. Geneva, June 28-July 31, 1998.
7. Anonymous. Protease inhibitors may increase blood glucose in HIV patients. FDA Med Bull 1997;27(2). Available from: www.FDA.gov/medbull/protease.html.
8. James JS. Protease inhibitor metabolic side effects: cholesterol, triglyceride, blood sugar and "Crixbelly." AIDS Treatment News, August 15, 1977.
9. Carr A, Cooper D. Lipodystrophy associated wilh an HIV-protease inhibitor. N Engl J Med 1998;339:1296.
10. Lipsky JJ. Abdominal fat accumulation in patients with HIV-1 infection. Lancet. 1998;351:847-8.
11. Mishriki YY. Baffling case of bulging belly, Protease punch. Postgrad Med 1998;104(3):45-6.
12. Madge S, Kinloch-De Loes S, Tyrer M, Johnson MA. Lipodystrophy syndrome (LS) in patients on reverse transcriptase inhibitors [abstr]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic-Infections, Chicago, January 31-February 4, 1999.
13. Saint-Marc T, Poizot-Martin I, Partisani M, Fabre J, Touraine JL. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy [abstr]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
14. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
15. Kotler DP, Rosenbaum K, Wang J, Pierson R. Studies of body composition and fat distribution in HIV-infected and control subjects. J AIDS 1999;20(3):228-37.
16. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
17. Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitor. AIDS 1998;12:F51-8.
18. Miller KD, Jones E, Yonavski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
19. Kotler DP. Update on lipid abnormalities and cardiovascular complications in HIV infection. Symposium, San Diego [online], October 20, 1998. Available from: http://www. medscape.com/medscape/HlV/treatmentupdate/1998/tu05/publ ic/toc/tu05.html.
20. Kotler DP. Truncal obesity "Crix-belly" - is it what it appears to be or something else? Clinical care option for HIV monthly experts column [online], February 14, 1998. Available from: http//healtheg.com/hiv/updales/feb98.
21. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-infection. Lancet 1998; 351:871-5.
22. Aboulafia D, Bundow D. Buffalo hump in a patient wilh the acquired immunodeficiency syndrome [letter]. N Engl J Med 1998;339:1297.
23. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitor [letter]. Lancet 1997;350:1596.
24. Herry I, Bernard L, de Truchis P, Perrone C. Hypertrophy of the breasts in patients treated with indinavir. Clin Infect Dis 1997;25:937-8.
25. Dube MP, Johnson DL, Currier JS. Protease inhibitor-associated hyperglycaemia [letter]. Lancet 1997;350:317.
26. Dong K, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J AIDS 1999;21:107-13.
27. Ward D, Delaney K, Moorman A, et al. Clinical factors related to lipodystrophy severity in the HIV outpatient study (HOPS) [abstr]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
28. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9.
29. Glesby M, Desai A, Erbelding E, Kostman J. High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy [abstr]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
30. Kotler DP. Summary report of the First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, June 26-28, 1999. Available from: www. medscape.com/Medscape/HlV7journal/1999/v05.n04/mha0712. kotl/mha0712.kotl-01.html.
31. Polo R, Verdejo M, Gonzalez-Munoz M, et al. Lipodystrophy related to NRT inhibitors in HAART therapy [abstr]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
32. Carr A, Samsaras K, Chisholm D, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351: 1881-3.
33. Stevens GJ, Chen M, Grecko R, et al. Preclinical investigations into the mechanism by which HIV protease inhibitors may induce metabolic disorders [abstr]. In: Program and Abstracts of the 39th Interscience Conference or Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
34. Mulligan K, Tai VW, Algren H, Chernoff DN, Lo JC, Schambelan M. Evidence of unique metabolic effects of protease inhibitors [abstr]. In: Program and Abstracts of the 5th Conference of Retroviruses and Opportunistic Infections, Chicago, February 2-6, 1998.
35. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-15.
36. Gallet B, Pulik M, Genet P, Chedin P, Hillgen M. Vascular complications associated with use of HIV protease inhibitor [letter]. Lancet 1998;351:1958-60.
37. Henry K, Melore H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitor [letter]. Lancet 1998;351:1328.
38. Behren G, Schmidt H, Meyer D, Stoll M. Vascular complications associated with use of HIV protease inhibitor [letter]. Lancet 1998;351:1958-60.
39. Escaut DV, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitor [letter]. Lancet 1998;351:1958-60.
40. Laurence J. Vascular complications associated with use of HIV protease inhibitor [letter]. Lancet 1998;351:1958-60.
41. Juette A, Salzeberg B, Franzen C, Roemer K, Diehl V, Factkenheuer G. Increase morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitor [abstr]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
42. Carr A, Thorisdottir A, Samaras K, Kaufmann GR, Chisholm DJ, Cooper DA. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PI or switching to nelfinavir [abstr]. In: Program and abstracts the 6th conference on retroviruses and opportunistic infections, Chicago, January 31-February 4, 1999.
43. Martinez E, Lazano L, Conget I, Casamitjana R, Gatell J. Reversion of metabolic abnormalities after switching HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
44. Moyle G, Baldwin C, Dent N, Gazzard B Management of protease inhibitor (PI)-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV+ persons [abstr]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
45. Henry K, Melroe H, Huebesch J, Kopaczewski J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-43.
46. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-I (+) patients [abstr]. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 24-27, 1998.
47. Polo R, Verdejo J, Gonzalez-Munoz M, et al. Switch to AZT+3TC improves lipodystrophy signs in the presence of protease inhibitors [abstr]. In: Programs and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
48. Walli RK, Michl GM, Rogner JR, et al. Effects on the PPAR-activator troglitazone on protease associated peripheral insulin resistance [abstr]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
49. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) [abstr]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
50. Torres R, Unger K. The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution syndrome [abstr]. In: Programs and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
51. Snatos GA, Finkelstein J, Pettit R. Management of HIV-associated adipose redistribution syndrome (HARS) in women with low-dose recombinant human growth (r-hGH) [abstr]. In: Programs and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999.
52. Lee D, Mathews WC. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV infected patients on protease inhibitor therapy [abstr], In: Programs and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.